3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
200
Breast Neoplasms
124
Carcinoma, Non-Small-Cell Lung
121
Glioblastoma
93
Neoplasms
75
Ovarian Neoplasms
72
Rectal Neoplasms
61
Brain Neoplasms
59
Lung Neoplasms
56
Colonic Neoplasms
55
Neoplasm Metastasis
51
Glioma
49
Carcinoma, Renal Cell
46
Fallopian Tube Neoplasms
38
Gliosarcoma
35
Pancreatic Neoplasms
31
Carcinoma, Hepatocellular
28
Melanoma
26
Adenocarcinoma of Lung
24
Astrocytoma
21
Stomach Neoplasms
20
Uterine Cervical Neoplasms
16
Recurrence
16
Prostatic Neoplasms
16
Liver Neoplasms
16
Adenocarcinoma, Bronchiolo-Alveolar
16
Esophageal Neoplasms
15
Adenocarcinoma
15
Carcinoma, Ovarian Epithelial
14
Kidney Neoplasms
13
Interventions
Paclitaxel
2
Carboplatin
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
temsirolimus
1
niraparib
1
carboprost tromethamine
1
Trabectedin
1
Preoperative Care
1
Postoperative Care
1
Ocoxin
1
Intraoperative Care
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
GX-188 vaccine
1
Filgrastim
1
Dexamethasone
1
Connor-Davidson Resilience Scale
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Genital Diseases, Female
×
Bevacizumab
×
Clear all
NCT01462890
2022-07-20
BOOST
AGO Study Group
Phase 3
Completed
927 enrolled